ADA 86th Scientific Sessions 2026: Outcomes Summary

The American Diabetes Association’s 86th Scientific Sessions closed Monday, June 8, 2026 in New Orleans after four days of late-breaking Phase 3 data that may be the most consequential single edition of the conference in years. Phase 3 results for five separate drug programs — the oral GLP-1 orforglipron (Foundayo), the triple-hormone-receptor agonist retatrutide, Novo Nordisk’s CagriSema combination, the dual GLP-1/glucagon agonist survodutide, and the PCSK9 inhibitor evolocumab — were presented at the meeting, with several simultaneously published in peer-reviewed journals [Ref. 1, Ref. 2, Ref. 4]. The conference also produced a formal practice paradigm shift with the unveiling of the 2026 ADA Standards of Care, which elevated cardiovascular and kidney risk reduction to co-primary treatment goals alongside glycemic control [Ref. 4].

This article summarizes what was presented at ADA 2026 and what the outcomes mean for the broader research understanding of GLP-1-class compounds and cardiometabolic peptide pharmacology. It serves as the natural companion to our ADA 2026 preview article published before the conference began.

Retatrutide TRIUMPH-1 + TRANSCEND-T2D-1: The Headline Story

The most-anticipated single presentation at ADA 2026 delivered. Eli Lilly presented detailed Phase 3 results across two retatrutide trials at a Saturday June 6 symposium, with additional positive results announced over subsequent days [Ref. 1].

TRIUMPH-1 detailed results. The 2,339-participant Phase 3 obesity trial showed retatrutide delivered powerful weight loss of up to an average of 70.3 lbs (28.3%) at 80 weeks in adults with obesity [Ref. 1]. The detailed data extended the topline results announced May 21, 2026 (covered in our TRIUMPH-1 Phase 3 results article) with cardiometabolic endpoints, subgroup analyses, and additional safety detail.

TRANSCEND-T2D-1 simultaneously published in The Lancet. The Phase 3 type 2 diabetes trial showed retatrutide lowered A1C by up to an average of 2.0% and weight by up to an average of 36.6 lbs (16.8%) at 40 weeks in adults with type 2 diabetes [Ref. 1]. The simultaneous Lancet publication signals the trial’s scientific significance — peer-reviewed publication in The Lancet at the same time as conference presentation is reserved for the most consequential clinical trial outcomes.

Beyond weight and glycemic endpoints. Additional retatrutide TRIUMPH program data presented at the conference showed meaningful improvements in knee osteoarthritis pain, moderate-to-severe obstructive sleep apnea, and other common obesity-related conditions [Ref. 1]. This represents an important extension of retatrutide’s evidence base — from pure obesity outcomes to broader obesity-complication outcomes that have implications for clinical positioning and reimbursement considerations.

CagriSema REIMAGINE 1-3: Novo Nordisk Delivers

Novo Nordisk’s CagriSema (the fixed-dose combination of cagrilintide and semaglutide) Phase 3 REIMAGINE program presented across three trials on Sunday June 7 [Ref. 2]. All three trials met their primary endpoints, demonstrating significant HbA1c reductions and confirming weight loss benefits in adults with type 2 diabetes.

REIMAGINE 2 superiority detail. The component-comparison trial directly compared CagriSema 2.4 mg/2.4 mg against semaglutide 2.4 mg monotherapy [Ref. 5]. Over 68 weeks, CagriSema reduced HbA1c by 1.91% and weight by 14.2%, outperforming semaglutide 2.4 mg (1.75% HbA1c reduction and 10.2% weight reduction) and cagrilintide alone [Ref. 5]. The data demonstrates that the cagrilintide + semaglutide combination produces incrementally better outcomes than either component alone — supporting CagriSema’s clinical positioning as a next-generation amylin/GLP-1 combination compound.

REIMAGINE 3 basal insulin add-on. The 274-participant trial tested CagriSema as an add-on to basal insulin in adults with long-standing diabetes [Ref. 5]. The combination drove HbA1c reductions of more than 2 percentage points and weight loss of up to 12% with no severe hypoglycemia and without increasing insulin doses. This is clinically important — type 2 diabetes patients on basal insulin represent a population where additional glycemic control with weight benefit is particularly valuable.

Simultaneous Lancet publications. REIMAGINE 1 and 2 results were simultaneously published in The Lancet Diabetes & Endocrinology, with REIMAGINE 3 results published in The Lancet [Ref. 2]. The Lancet publications add peer-reviewed scientific authority to the conference presentations — and parallel the simultaneous Lancet publication of TRANSCEND-T2D-1, signaling that ADA 2026 was a particularly substantial conference for The Lancet’s cardiometabolic trial coverage.

Foundayo (Orforglipron) ACHIEVE Program

Eli Lilly also presented detailed Phase 3 results for Foundayo (orforglipron), the recently approved oral nonpeptide GLP-1 receptor agonist [Ref. 1]. The ACHIEVE program presentations included head-to-head data versus oral semaglutide (ACHIEVE-3) and comparison with dapagliflozin (ACHIEVE-2), establishing Foundayo’s positioning in the oral GLP-1 landscape.

The Foundayo data is notable because the compound is the first oral nonpeptide GLP-1 to reach approval, taken without food or water restrictions — distinguishing it from oral semaglutide which requires fasting and specific water restrictions for absorption [Ref. 3]. The ADA presentations confirm Foundayo’s clinical effectiveness in both type 2 diabetes glycemic control and obesity-related endpoints.

Survodutide SYNCHRONIZE-1: The Dark Horse

Boehringer Ingelheim and Zealand Pharma’s survodutide, a dual GLP-1/glucagon receptor agonist with FDA Fast Track and Breakthrough Therapy designations, presented Phase 3 SYNCHRONIZE-1 data showing substantial placebo-adjusted weight loss and waist-circumference reductions in non-diabetic obesity [Ref. 3]. The compound’s dual GLP-1/glucagon mechanism sits between the single-agonist Semaglutide and the triple-agonist Retatrutide on the spectrum of incretin pharmacology — adding glucagon receptor activation to GLP-1 but not adding GIP receptor activation.

Survodutide’s positioning in the broader incretin landscape is one of the key open questions emerging from ADA 2026. The compound’s mechanism diversity (dual-agonist with hepatic effects from the glucagon component) and Breakthrough Therapy designation suggest meaningful potential, though the head-to-head positioning against Retatrutide’s triple-agonist mechanism remains to be characterized in direct comparison trials.

The Structural Story: 2026 ADA Standards of Care Paradigm Shift

The conference also unveiled the 2026 ADA Standards of Care, formally elevating cardiovascular and kidney risk reduction to co-primary treatment goals alongside glycemic control [Ref. 4]. This represents a formal practice paradigm shift in diabetes care — ending decades of practice in which A1C stood as the dominant benchmark.

Key Standards of Care updates with implications for the broader cardiometabolic peptide research landscape:

• Therapy selection by cardiometabolic benefit. The 2026 guidelines place significant emphasis on selecting glucose-lowering therapies with cardiometabolic benefits — for cardiovascular, heart failure, and kidney health — irrespective of HbA1c level. This positions GLP-1 receptor agonists with established cardiovascular outcomes data (Semaglutide via SUSTAIN-6/SELECT) at the center of practice recommendations.
• GLP-1 use in chronic kidney disease. A new recommendation provides guidance on initiation or continuation of GLP-1-based therapy in individuals on dialysis to reduce cardiovascular risk — expanding the population in whom GLP-1 use is formally supported.
• MASH and symptomatic heart failure. Recommendations now support GLP-1 or dual GIP/GLP-1 receptor agonists when evidence shows benefit — formalizing the use of these compounds beyond their original type 2 diabetes and obesity indications.
• Obesity pharmacotherapy individualization. Recommendations emphasize individualized dosing and titration to optimize efficacy, minimize adverse effects, and enhance medication adherence — implicitly acknowledging that the maximum approved dose is not always the optimal treatment dose for every patient.
• Inaugural 2026 Standards of Care in Overweight and Obesity. The conference also released a separate dedicated Standards of Care document for overweight and obesity treatment — the first comprehensive evidence-based clinical guidance the ADA has issued specifically for obesity management as distinct from diabetes management.

The Standards of Care updates have implications well beyond any single compound. They formally codify what the cardiometabolic research community has been moving toward over the past several years — treating cardiovascular and kidney outcomes as part of the same disease process as obesity and diabetes, and selecting therapies based on integrated cardiometabolic benefit rather than glycemic control alone.

Where the Cardiometabolic Pipeline Stands After ADA 2026

The conference outcomes substantially clarify the cardiometabolic pipeline picture. The pipeline depth across multiple companies, multiple mechanisms, and multiple development stages now establishes the broader research conversation that GLP-1-class compounds will operate within for the next several years.

Approved compounds with continuing data expansion:

• Semaglutide (Ozempic, Wegovy, Rybelsus — Novo Nordisk) — continuing cardiovascular and kidney outcomes data
• Tirzepatide (Mounjaro, Zepbound — Eli Lilly) — continuing data across multiple indications
• Foundayo / orforglipron (Eli Lilly) — first oral nonpeptide GLP-1, recently approved with continuing data expansion

Investigational compounds with Phase 3 data presented:

• Retatrutide (Eli Lilly) — triple-agonist with TRIUMPH-1 obesity and TRANSCEND-T2D-1 type 2 diabetes data
• CagriSema (Novo Nordisk) — cagrilintide + semaglutide combination with REIMAGINE 1-3 type 2 diabetes data
• Survodutide (Boehringer Ingelheim / Zealand Pharma) — dual GLP-1/glucagon with SYNCHRONIZE-1 obesity data

Investigational compounds with Phase 2 data presented:

• Zenagamtide (Novo Nordisk) — novel once-weekly GLP-1/amylin combination, Phase 2 data presented

Earlier-stage compounds with pipeline visibility:

• Elecoglipron (Eli Lilly oral) — earlier oral GLP-1 candidate
• AZD5004 (AstraZeneca) — moving to Phase 3 on SOLSTICE data
• ASC30, ASC37, ASC39 (Ascletis Pharma) — diversified obesity portfolio including small-molecule and peptide candidates

The pipeline diversity confirms what BioSpace characterized in pre-conference coverage as “obesity Davids and Goliaths” — the dominant pharmaceutical companies are facing meaningful competition from biotech challengers across multiple compound classes and mechanism approaches.

What This Means for Research

The pharmaceutical pipeline outcomes presented at ADA 2026 inform the broader peptide research landscape in several ways relevant for researchers working with research-grade compounds.

Triple-agonist mechanism Phase 3-validated. The triple-agonist mechanism that retatrutide is built on has now received Phase 3 validation across both obesity (TRIUMPH-1) and type 2 diabetes (TRANSCEND-T2D-1) populations. The mechanism understanding covered in our Retatrutide deep dive is supported by the most current Phase 3 evidence available.

Combination therapy validation. The CagriSema REIMAGINE results validate the cagrilintide + semaglutide combination approach — a different combination strategy than the single-molecule multi-agonist approach that retatrutide and tirzepatide represent. Both combination strategies (fixed-dose combination vs single-molecule multi-receptor activation) now have Phase 3 validation, expanding the mechanism landscape for cardiometabolic peptide research.

Comparison landscape updated. The detailed Phase 3 data substantially expands the comparative landscape for researchers studying GLP-1-class compounds. Our GLP-1 research comparison and Semaglutide vs Retatrutide focused comparison will be updated to reflect the most current data.

Regulatory framing remains unchanged. ADA presentations of clinical trial data do not change the regulatory status of investigational compounds. Retatrutide, CagriSema, survodutide, zenagamtide, and other investigational compounds remain unapproved by FDA, Health Canada, EMA, and other regulatory agencies regardless of the strength of the Phase 3 data presented. Research-grade material continues to be intended for laboratory research only.

Sourcing Research-Grade Compounds

For researchers studying GLP-1-class compounds in laboratory contexts, Semaglutide, Tirzepatide, and Retatrutide are available through the Kinetic Compounds catalog with batch-specific Certificates of Analysis from Janoshik Analytical published on each product page.

Complete mechanism and research background for these compounds is covered in our individual deep dives: Semaglutide, Tirzepatide, and Retatrutide, with head-to-head comparison in our GLP-1 research comparison and Semaglutide vs Retatrutide focused comparison.

Research-grade material is intended exclusively for laboratory research and is not a substitute for any approved pharmaceutical product. The trial outcomes presented at ADA 2026 do not change this framing — the pharmaceutical compounds and the research-grade compounds operate under different regulatory frameworks.

For deeper research background on the compounds discussed in this article, see our Semaglutide deep dive, Tirzepatide deep dive, Retatrutide deep dive, GLP-1 trilateral comparison, and Semaglutide vs Retatrutide focused comparison. Research-grade material for laboratory research is available through our research peptide catalog with current Certificates of Analysis on every product page.